Pharmacotherapy, particularly glucagon-like peptide-1 (GLP-1) receptor agonists such as liraglutide and semaglutide, and metabolic/bariatric surgery are recommended as adjunctive options for carefully selected adolescents with severe obesity and significant comorbidities. In Poland, published reports and policy analyses suggest that implementation is often constrained by delayed access to specialist obesity services and structured lifestyle-behavioral support, as well as limited reimbursement for anti-obesity medications. This evidence concerns the gene GCG and Obesity.